Nicolai Obling

Nicolai Obling

Auto-generated profile, based on publicly available information

Nicolai Obling

Department of Respiratory Medicine, Zealand University Hospital Næstved, Denmark; Institute for Regional Health Research, University of Southern, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
LFLaurits Frøssing
Laurits Frøssing
DKDitte K. Klein
Ditte K. Klein
MHMorten Hvidtfeldt
Morten Hvidtfeldt
NONicolai Obling
Nicolai Obling
GTGunilla Telg
Gunilla Telg
CPCeleste Porsbjerg
Celeste Porsbjerg
Background: Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population.Methods: Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×109 cells·L−1and 3% respectively), total IgE (≥150 U·mL−1), and fractional exhaled nitric oxide (≥25 ppb).Results: Patients with mild-to-moderate asthma were younger (41versus49 years, p<0.001), had lower body mass index (25.9versus28.0 kg·m−2, p=0.002) and less atopy (47%versus58%, p=0.05), higher forced expiratory volume in 1 s (3.2versus2.8 L, p<0.001) and forced vital capacity (4.3versus3.9 L, p<0.001) compared with patients with severe asthma, who had higher blood (0.22×109versus0.17×109 cells·L−1, p=0.01) and sputum (3.0%versus1.5%, p=0.01) eosinophils. Co-expression of all T2 biomarkers was a particular characteristic of severe asthma (p<0.001). In patients with eosinophilia, sputum eosinophilia without blood eosinophilia was present in 45% of patients with mild-to-moderate asthma and 35% with severe asthma.Conclusion: Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.

22 February 2022 in Respiratory Medicine
Verified
Journal Article
Open access
NONicolai Obling
Nicolai Obling
VBVibeke Backer
Vibeke Backer
JHJohn Hurst
John Hurst
UBUffe Bødtger
Uffe Bødtger
Systemic inflammation is a well-established feature of Chronic Obstructive Pulmonary Disease, COPD, but less is known about inflammation in the upper airways in the disease. In the current study, we investigated the inflammatory profile in the upper airway and in serum in a cohort of patients with COPD. Patients were examined with inflammatory profiles measured on material from the upper airway and in serum using a 14-plex Bioplex multiplex immunoassay containing the following cytokines: IL-1-beta, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, IL-18, Interferon-gamma, Tumour Necrosis Factor-alpha, Tumour Necrosis Factor beta, and GM-CSF. We evaluated COPD disease burden using the CAT questionnaire and symptoms from the upper airways with the nasal domain of the 22 items Sino Nasal Outcome Test (SNOT22nasal). We included 180 patients (female 55%, age 67 (±8) years, FEV1% 52.4 (±16.6). Using a SNOT22nasal threshold of ≥6, we divided patients into high upper airways symptoms (high UAS), n = 74 (41%) and low upper airway symptoms (low UAS), n = 106 (59%). High UAS was significantly associated with higher levels of IL-1 beta and IL-3 in nasal samples (p = 0.016 and 0.02, respectively) and higher serum levels of IL-1 beta (p = 0.003). Upper airway scores correlated positively with nasal levels of IL-3 (rho = 0.195, p = 0.01) and serum levels of IL-1 beta (rho = 0.226, p = 0.005). Patients with COPD and high upper airway symptoms displayed signs of eosinophilic and neutrophilic inflammation with elevated levels of IL-1 beta and IL-3 in the nose and elevated IL-1 beta in serum.

1 January 2020 in European Clinical Respiratory Journal
Verified
Journal Article
Open access
VBVibeke Backer
Vibeke Backer
DKDitte K. Klein
Ditte K. Klein
UBUffe Bødtger
Uffe Bødtger
KRKerstin Romberg
Kerstin Romberg
CPCeleste Porsbjerg
Celeste Porsbjerg
LBLeif Bjermer
Leif Bjermer
Background: The BREATHE study is a cross-sectional study of real-life patients with asthma and/or COPD in Denmark and Sweden aiming to increase the knowledge across severities and combinations of obstructive airway disease. Design: Patients with suspicion of asthma and/or COPD and healthy controls were invited to participate in the study and had a standard evaluation performed consisting of questionnaires, physical examination, FeNO and lung function, mannitol provocation test, allergy test, and collection of sputum and blood samples. A subgroup of patients and healthy controls had a bronchoscopy performed with a collection of airway samples. Results: The study population consisted of 1403 patients with obstructive airway disease (859 with asthma, 271 with COPD, 126 with concurrent asthma and COPD, 147 with other), and 89 healthy controls (smokers and non-smokers). Of patients with asthma, 54% had moderate-to-severe disease and 46% had mild disease. In patients with COPD, 82% had groups A and B, whereas 18% had groups C and D classified disease. Patients with asthma more frequently had childhood asthma, atopic dermatitis, and allergic rhinitis, compared to patients with COPD, asthma + COPD and Other, whereas FeNO levels were higher in patients with asthma and asthma + COPD compared to COPD and Other (18 ppb and 16 ppb vs 12.5 ppb and 14 ppb, p < 0.001). Patients with asthma, asthma + COPD and Other had higher sputum eosinophilia (1.5%, 1.5%, 1.2% vs 0.75%, respectively, p < 0.001) but lower sputum neutrophilia (39.3, 43.5%, 40.8% vs 66.8%, p < 0.001) compared to patients with COPD. Conclusions: The BREATHE study provides a unique database and biobank with clinical information and samples from 1403 real-life patients with asthma, COPD, and overlap representing different severities of the diseases. This research platform is highly relevant for disease phenotype- and biomarker studies aiming to describe a broad spectrum of obstructive airway diseases.

25 June 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
NONicolai Obling
Nicolai Obling
VBVibeke Backer
Vibeke Backer
JHJohn Hurst
John Hurst
UBUffe Bødtger
Uffe Bødtger
Background: There is growing evidence that upper airway symptoms coexist with lower airway symptoms in COPD. Still, the prevalence and impact of upper airway disease on the nature and course of COPD remain unclear. We aimed to describe this in a cross-sectional study.Methods: We examined a cohort of COPD patients with pulmonary function tests, induced sputum, blood eosinophils, atopy tests and computed tomography (CT) of the paranasal sinuses. Lower airway symptoms were assessed using the COPD Assessment Test (CAT), and upper airway symptoms were assessed using the nasal subdomain of the 22-item Sino Nasal Outcome Test (SNOT22nasal). We recruited patients from five sites in Denmark and Sweden. We excluded patients with a history of asthma.Findings: In total, 180 patients (female 55%, age 67±8 years, forced expiratory volume in 1 s (FEV1%) 52.4±16.6, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage: A: 18%, B: 54%, C: 3%, D: 25%) were included in the study. Seventy-four patients (41%) reported high upper airway symptoms (UAS, defined as SNOT22nasal≥6) with a median score of 10 (IQR 8–13). Patients with high UAS reported higher CAT scores (17.4±7.5versus14.9±6.6, p<0.05) and displayed higher fractions of eosinophils in blood (median 3.0% (IQR 1.6–4.2%)versus2.3% (IQR 1.4–3.1%), p<0.05) and in induced sputum (median 1.8% (IQR 0.3–7.1%)versusmedian 0.5% (IQR 0–1.7%), p<0.05). No differences in atopy, CT findings or exacerbation rates were observed.Conclusion: COPD patients with upper airway disease showed increased evidence of eosinophilic disease and increased lower airway symptom burden.

1 January 2022 in Respiratory Medicine
Verified
Journal Article
Open access
NONicolai Obling
Nicolai Obling
BRBojidar Rangelov
Bojidar Rangelov
VBVibeke Backer
Vibeke Backer
JHJohn Hurst
John Hurst
UBUffe Bødtger
Uffe Bødtger
Small Airways Disease (SAD) is a recognised part of the pathology in Chronic Obstructive Pulmonary Disease (COPD) and contributes to the symptom burden in the disease. Upper airway symptoms in COPD is an emerging field of study, and in this study, we sought to examine the co-existence of SAD and upper airways symptoms in a cohort of COPD patients METHODS: We investigated a cohort of patients with COPD for the presence of SAD with three different modalities. We performed High-Resolution CT (HRCT) with Parametric Response Mapping (PRM) analysis and recorded distribution of emphysema (PRMEmph) and functional Small Airways Disease (PRMfSAD). We measured central and peripheral lung resistance using Impulse Oscillometry (IOS) and recorded R5Hz, R20Hz, R5-R20Hz, X5, Fres and Ax. Static lung function parameters were obtained using Body Plethysmography. Data on upper and lower airway symptoms were evaluated using the Upper Airway subdomain of the 22 items Sino Nasal Outcome Test (SNOT22nasal) and the COPD Assessment Test (CAT), respectively. We recruited a total of 112 patients. (female sex: 58%, Age 68 (±8) years, FEV1%predicted: 53% (±16%), GOLD stage: A: 23%, B: 55%, C:1% D: 21%). Forty-five (40%) were classified as having high upper airway symptoms (UAS), defined as SNOT22nasal ≥6. Eighty-seven per cent showed signs of SAD using IOS (R5-R20Hz > 0.07 kPa/L/s). No significant differences were found between UAS groups in IOS, PRM or Body Plethysmography parameters. In patients with COPD, the prevalence of small airways disease was very high, but no association between upper airway symptoms and small airways disease was demonstrated.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
NONicolai Obling
Nicolai Obling
BRBojidar Rangelov
Bojidar Rangelov
VBVibeke Backer
Vibeke Backer
JHJohn R Hurst
John R Hurst
UBUffe Bodgter
Uffe Bodgter
Background: Small airways disease (SAD) and emphysema contribute to symptom burden in COPD. In this study, we sought to examine the prevalence of SAD and emphysema in a cohort of COPD patients and to investigate associations with lower and upper airway symptoms. In asthma, SAD and upper airways symptoms are associated. Methods: We examined patients from the BREATHE cohort with High-Resolution CT (HRCT) and subsequent Parametric Response Mapping (PRM) analysis and recorded distribution of emphysema (EmpPRM) and functional Small Airways Disease (fSADPRM). We evaluated upper and lower airway symptoms using the Upper Airway subdomain of the 22 items Sino Nasal Outcome Test (SNOT22UAS, cut-off ≥ 6 points) and the COPD Assessment Test (CAT), respectively. Dynamic and static lung function tests were measured. Findings: Sixty patients were enrolled (female sex: 52%, age: 67 (±8.3) years, FEV1%predicted: 50.3% (±17.8%), GOLD stage: A: 16%, B: 53%, D: 30%). 22 patients (36%) reported significant upper airway symptoms. The mean levels of EmpPRM and fSADPRM were 25.1% (±13.3%) and 39.5% (±5.2%) respectively. We found no significant association between HRCT scores (EmpPRM or fSADPRM) and symptom burden (CAT score or SNOT22UAS), despite both HRCT scores correlating significantly and positively with hyperinflation (Residual Volume and Total Lung Capacity) and negatively with FEV1 and diffusion capacity. Conclusion: Functional small airways disease and emphysema are widespread features of COPD, but in the current study not clearly associated with symptom burden.